Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Market Closed - Nyse Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
1.21 ^USD	-.--%		-1.63%	-55.51%

15/05	CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
08/05	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05	AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05	BU
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05	AQ
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05	BU
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	19/03	BU
CEL-SCI Corporation Issues Letter to Shareholders	06/03	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	15/02	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	15/02	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	13/02	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	12/02	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	09/02	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	07/02	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	06/02	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	01/02	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	31/01	BU
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments	22/12	BU
UK'S National Institute for Health and Care Excellence Selects CEL-SCI's Multikine as Potential New Standard of Care for Head and Neck Cancer	05/12	AQ
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer	04/12	BU
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock	21/11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Press Releases

Filters